Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111085 · ClinicalTrials.gov registry record · Phase 2
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 413
- Enrollment target
NCT00111085 is a Phase 2 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 413 participants.
The verdict
NCT00111085, a Phase 2 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 413 participants
- Enrollment target
Study Summary
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
Interventions
- DRUG Placebo
- DRUG Clazosentan 1 mg/h
- DRUG Clazosentan 5 mg/h
- DRUG Clazosentan 15 mg/h
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2005-01-10 |
| Est. Completion | 2006-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111085
The ClinicalTrials.gov registry entry for NCT00111085 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00111085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00111085 about?
NCT00111085 is a clinical study titled "Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)". The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
What is the current status of trial NCT00111085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 413 participants. The study started on 2005-01-10. Estimated completion is 2006-03-30.
What interventions are being tested in trial NCT00111085?
The interventions under investigation include: Placebo (DRUG), Clazosentan 1 mg/h (DRUG), Clazosentan 5 mg/h (DRUG), Clazosentan 15 mg/h (DRUG).
Who is sponsoring clinical trial NCT00111085?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.